Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ConocoPhillips (COP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ConocoPhillipsTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ConocoPhillips vs Inovio Pharmaceuticals Inc — how do they compare? ConocoPhillips trades at $125.67 (market cap $151.27B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: ConocoPhillips is far larger — about 1925.8× Inovio Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 2.67% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

COPINO
Market Cap
$151.27B$78.55M
Sector
EnergyHealth
52-Week High
$133.80$2.87
52-Week Low
$85.66$0.66
Enterprise Value
$166.87B$49.56M
Dividend Yield
2.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ConocoPhillips

ConocoPhillips (COP) trades at $123.03, up 4.61% on the day, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The company reported EPS of $3.24 versus $2.90 expected, driven by higher oil prices and Permian Basin output. Recent CEO transition to Andy O'Brien signals continuity, with a consensus analyst price target of $150.00 indicating 22% upside potential.

Outlook remains positive due to robust free cash flow growth and favorable commodity trends, though risks include oil price volatility and execution of the Alaska project. The stock offers value with a P/E of 16.66 and a net income margin of 14.65%, supported by a 74.51% buy rating from analysts.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO